OncoMatch/Clinical Trials/NCT06080061
Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer
Is NCT06080061 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies non-drug interventions for lung cancer.
The purpose of this study is to examine the use of hypofractionated accelerated radiation therapy (HART) to treat locally advanced lung cancer. Depending on the location and size of the tumor.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: radiation therapy
Exception: previous radiation therapy to the thorax that would result in overlapping high dose radiation fields
Previous radiation therapy to the thorax that would result in overlapping high dose radiation fields
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Stanford University · Palo Alto, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify